3 articles
Grape King announced its March 2026 monthly revenue reached 858 million yuan, a 7.0% decrease compared to the same period last year. The company operates in the biotechnology and healthcare sector.
Chroma announced its March 2026 revenue of 669.211 million yuan, marking an 18.2% increase compared to the same period last year. This performance highlights the company's strong growth within the biotechnology and medical industry.
Hospice (Stock Code: 1734), a company in the biotechnology and healthcare sector, reported its March 2026 revenue at NT$317.169 million, marking a 5.1% increase compared to the same period last year. This growth underscores the company's expanding presence and performance within the dynamic biotech and medical industry.